SynthesisScientific reports2026
The therapeutic potential of antibody-drug conjugates in advanced colorectal cancer: a systematic review and meta-analysis.
Synthesis in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
HER2-targeted antibody-drug conjugates (ADCs) have achieved clinically meaningful activity in several human epidermal growth factor-2 (HER2)-positive malignancies. However, the efficacy of these agents in HER2-positive colorectal cancer (CRC) remains incompletely understood.To address this gap, we conducted a systematic review and meta-analysis to compare treatment outcomes of HER2-targeted ADC therapy in patients with HER2-positive CRC versus those with HER2-positive tumors of other origins. Five prospective clinical studies evaluating HER2-targeted ADCs in HER2-positive malignancies were included. Outcomes assessed included disease control rate (DCR), objective response rate (ORR), partial response (PR), stable disease (SD), and progressive disease (PD). Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using fixed-effects models due to low heterogeneity. Four studies incorporating 45 patients with HER2-positive CRC and 107 patients with HER2-positive non-CRC tumors were included in the DCR analysis. No significant difference in DCR was observed between CRC and non-CRC cohorts (OR = 0.63, 95% CI: 0.25-1.57; p = 0.32), with minimal heterogeneity (Q(3) = 1.09, p = 0.78; I² = 0%). Five studies including 65 CRC patients and 189 non-CRC patients were analyzed for ORR. HER2-positive CRC patients exhibited a significantly lower ORR compared with patients with other HER2-positive malignancies (OR = 0.42, 95% CI: 0.20-0.88; p = 0.02), indicating that CRC patients were less than half as likely to achieve an objective response. Heterogeneity was negligible (Q(4) = 1.82, p = 0.77; I² = 0%). Four studies also assessed PR, SD, and PD. A trend toward reduced PR rates in CRC patients was observed but did not reach statistical significance (OR = 0.41, 95% CI: 0.16-1.07; p = 0.07; I² = 0%). Rates of SD were comparable between CRC and non-CRC cohorts (OR = 1.63, 95% CI: 0.74-3.61; p = 0.23; I² = 0%). Funnel plot analyses and statistical testing revealed no evidence of significant publication bias. While ADC therapy achieves disease control in HER2-positive CRC comparable to that in other HER2-positive malignancies, objective and partial response rates appear significantly lower. These findings suggest intrinsic differences in ADC sensitivity between CRC and other HER2-driven tumors and underscore the need for CRC-specific ADC development and biomarker-driven patient selection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.